SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant discussion following reports that Nvidia has paused evaluating its 18A chipmaking process, a crucial element of Intel's revitalized foundry strategy. However, much of the community is highly skeptical, calling the news old or manipulative, and arguing that 18A was primarily for internal use while future external foundry deals, potentially including Nvidia, are centered on the more advanced 14A node. Many investors express frustration over perceived short-term price suppression, yet maintain long-term confidence in Intel's competitive positioning.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is experiencing extreme volatility and intense investor focus as the market eagerly awaits an imminent FDA PDUFA decision for its life-saving drug, Narsoplimab, to treat TA-TMA. Following a trading halt for news pending, community sentiment is largely optimistic for approval, anticipating a significant price surge fueled by high short interest and the drug's first-in-class status for a condition with no existing treatment. The broader context of the recent de-risking deal with Novo Nordisk and previous regulatory hurdles fuels speculation of substantial long-term value and even a potential buyout, making this a pivotal moment for the company.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, which is touted as the largest commercial communications array ever deployed in low Earth orbit. This achievement is fueling significant bullish sentiment, with many anticipating the validation of its direct-to-device cellular broadband vision and rapid network expansion. However, discussions also reflect skepticism around the company's long-term profitability and current valuation, even as the community focuses on future scaling and execution milestones.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intensified speculation for a major partnership or buyout, catalyzed by a recent acquisition in the biotech sector and heightened discussions around its undervalued protein-based vaccine platform and combination influenza/COVID candidate. Shareholders are openly frustrated with management's perceived inaction and lack of communication, echoing an activist investor's push for a strategic review to unlock value from Novavax's differentiated non-mRNA technology, especially as concerns about mRNA vaccine safety grow. This confluence of factors, coupled with high short interest, positions the company for potentially significant market movement should a transformative deal be announced.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is a major talking point as Sanofi announced its acquisition for $15.50 per share, valuing the company at $2.2 billion and representing a substantial premium. This move integrates Dynavax's marketed adult Hepatitis B vaccine, its shingles candidate, and a recently licensed oral COVID-19 vaccine program into Sanofi's global immunization portfolio. While many long-term shareholders are relieved to see a resolution, a significant portion of the community feels the acquisition price undervalues the company's assets and growth prospects.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the market assesses its recently completed Marigold acquisition and updated strong guidance for future financial performance. Community discussions highlight optimism for its advanced AI platform and proprietary data in the evolving marketing sector, with many anticipating significant upside following its participation in an upcoming key industry event. Despite some short-term price fluctuations, investors are closely watching for its potential re-rating as an an undervalued AI-driven marketing powerhouse.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following the FDA's expanded approval of AQVESME (mitapivat) for adults with alpha- or beta-thalassemia, establishing it as the first and only oral treatment for this condition. The community is actively discussing the commercial implications and the drug's high cost, while also reflecting on broader concerns about management's communication style and historical execution.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is experiencing significant positive momentum, driven by its upcoming inclusion in the S&P MidCap 400 index, effective early next year. The community views this as a major catalyst for structural demand, anticipating increased institutional buying, enhanced liquidity, and greater visibility for the Agentic AI and automation leader.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust is surging to new all-time highs, driven by intensifying industrial demand from rapidly expanding sectors like AI data centers, EVs, and solar, alongside significant global supply concerns. The rally is further fueled by China's impending export restrictions on silver, with market participants eagerly discussing a potential 'silver squeeze' and a fundamental re-evaluation of its value, though some anticipate a near-term correction after its rapid ascent.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is heavily trending amid widespread speculation of an imminent buyout, fueled by recent significant insider purchases and strong financial fundamentals including growing Lupkynis sales and a robust cash position. The community is actively discussing the potential Phase 2 indications for AUR200, while many shareholders voice frustration over perceived management opacity and repeatedly call for a change in leadership to unlock further value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bank ETFs Shine as US Banking Profit Hits Decade High in Q3

Bank ETFs such as FTXO are drawing attention as U.S. banking profits reached a decade high in Q3 2025, setting the stage for continued gains in 2026.

Will 2026 be a Great Year for Banks? ETFs in Focus 

Could 2026 be a great year for banks as rates stabilize, credit demand rises and earnings surge? Bank ETFs like IYG, IYF, KBWB, XLF and VFH may benefit.

Should You Invest in the Invesco KBW Bank ETF (KBWB)?

Is First Trust NASDAQ Bank ETF (FTXO) a Strong ETF Right Now?

Should You Invest in the First Trust NASDAQ Bank ETF (FTXO)?

Legendary investor Warren Buffett-owned Berkshire Hathaway has trimmed its stake in Bank of America for the first time since 2019 over six trading sessions. Despite the stake reduction, retail investors have refrained from turning bearish on the stock with the sentiment meter trending in the neutral zone (53/100) supported by high message volume.<figure class="image"><img style="aspect-ratio:1586/460;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_25_at_11_14_56_AM_17542e5de1.png" alt="Retail sentiment trends in the neutral territory for Bank of America" width="1586" height="460"><figcaption>Retail sentiment trends in the neutral territory for Bank of America</figcaption></figure>The sale of shares took place from Wednesday July 17 through July 24, according to filings on the Securities and Exchange Commission (SEC) website. Last week, Berkshire sold roughly 33.89 million shares of the lender at prices ranging from $43.13 to $44.07. This week, the firm sold another 18.89 million shares at prices ranging from $42.39 to $42.56.In total, Berkshire sold 52.89 million shares of the lender in six sessions that amounts to approximately $2.30 billion worth of stock. However, Berkshire still holds over 980 million shares of the bank, worth $41 billion at current prices. That’s second only to its stake in Apple which is worth a whopping $172 billion.Notably, the share sale comes in the wake of a decent rally registered by Bank of America stock this year, having gained over 23% on a year-to-date (YTD) basis. The lender, too, has been doing well on its operational metrics. Last week, it announced an upbeat set of earnings that topped analyst estimates on multiple counts. The bank reported a revenue of $25.40 billion during the quarter which came in higher than a Street estimate of $25.22 billion. Earnings per share came in at 83 cents as compared to an estimate of 80 cents.But that’s not all. The bank has been in the news lately after it increased its common stock dividend by 8% to $0.26 per share. The Board also authorized a new $25 billion common stock repurchase program, effective August 1, 2024, to replace the company’s current program, which will expire on that date.Stocktwits users are chatting about the buyback and the dividend hike, but some aren’t optimistic about the stock post Berkshire’s selling. A user named ‘FOTIKRR’ believes the stock could fall below the $30 mark and Buffett’s stake reduction in the lender is a precursor for a downward move in the stock and the broader financial sector.<figure class="image"><a href="https://stocktwits.com/FOTIKRR/message/580483338"><img style="aspect-ratio:1572/648;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_25_at_11_16_53_AM_a736322b3a.png" alt="Stocktwits user FOTIKRR's post on Bank of America" width="1572" height="648"></a><figcaption>Stocktwits user FOTIKRR's post on Bank of America</figcaption></figure>Photo Courtesy: Bank of America website

Warren Buffett Unloads Bank of America: How Retail Investors Reacted

Retail investors are uncertain about the stock’s fate given that Buffett’s stake reduction comes amid Bank of America’s dividend hike and a $25 billion buyback.

FTXO
First Trust Exchange-Traded Fund III - First Trust Nasdaq Bank ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FTXO News

FTXOFirst Trust Exchange-Traded Fund III - First Trust Nasdaq Bank ETF